2024
Pathologic complete response (pCR) rates for patients with HR+/HER2− high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial
Huppert L, Wolf D, Yau C, Brown-Swigart L, Hirst G, Isaacs C, Pusztai L, Pohlmann P, DeMichele A, Shatsky R, Yee D, Thomas A, Nanda R, Perlmutter J, Heditsian D, Hylton N, Symmans F, Veer L, Esserman L, Rugo H. Pathologic complete response (pCR) rates for patients with HR+/HER2− high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial. Annals Of Oncology 2024, 36: 172-184. PMID: 39477071, DOI: 10.1016/j.annonc.2024.10.018.Peer-Reviewed Original ResearchDistant recurrence-free survivalEarly-stage breast cancerPathological complete responsePathologic complete response rateClinical/molecular featuresComplete responseER-positiveBreast cancerRate of pathological complete responseResponse to neoadjuvant chemotherapyRecurrence-free survivalI-SPY2 trialOptimal treatment selectionNeoadjuvant armER/PR statusLobular histologyNeoadjuvant chemotherapyIII diseaseImmune signaturesNegative diseaseOptimal therapyI-SPY2Excellent outcomesTreatment armsFollow-up
2023
Does Preoperative MRI Reduce Positive Margins after Breast-Conserving Surgery?
Cairns A, Chagpar A, Dupont E, Levine E, Gass J, Chiba A, Ollila D, Howard-McNatt M. Does Preoperative MRI Reduce Positive Margins after Breast-Conserving Surgery? Annals Of Surgical Oncology 2023, 30: 6053-6058. PMID: 37505353, DOI: 10.1245/s10434-023-13884-8.Peer-Reviewed Original ResearchConceptsPreoperative magnetic resonance imagingMagnetic resonance imagingExtensive intraductal componentMargin statusPositive marginsTumor sizeTumor factorsMedian tumor sizeBreast conserving surgeryBreast cancer managementInvasive lobular histologyNeoadjuvant chemotherapyLobular histologyIntraductal componentMedian ageMulticenter trialPatient agePalpable tumorsPatient factorsShave marginsNegative marginsResultsA totalAssociated FactorsBreast cancerUS CentersMetastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study.
Fanucci K, Lustberg M, Fischbach N, Pelletier M, Sivapiragasam A, Ashok Kumar P, Kallem M, Danziger N, Sokol E, Sivakumar S, Pavlick D, Ross J, Pusztai L. Metastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study. Journal Of Clinical Oncology 2023, 41: 1036-1036. DOI: 10.1200/jco.2023.41.16_suppl.1036.Peer-Reviewed Original ResearchMetastatic breast cancerLobular histologyBreast cancerHER2 IHCGenomic alterationsComprehensive genomic profiling studyPD-L1 gene amplificationImmune checkpoint inhibitor treatmentMicrosatellite instabilityAxillary LN metastasisMetastatic site biopsySubset of ptsStage IV diseaseCheckpoint inhibitor treatmentPD-L1 expressionTumor mutational burdenMutations/MbMSI-high statusHER2 IHC resultsGenomic profiling studiesSite biopsiesSP142 assayLN metastasisMetastatic diseaseHigh TMB
2022
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast CancerNeratinib and Fulvestrant in HER2-Mutated Breast Cancer
X. C, Luo J, Freedman RA, Pluard TJ, Nangia JR, Lu J, Valdez-Albini F, Cobleigh M, Jones JM, Lin NU, Winer EP, Marcom PK, Thomas S, Anderson J, Haas B, Bucheit L, Bryce R, Lalani AS, Carey LA, Goetz MP, Gao F, Kimmick G, Pegram MD, Ellis MJ, Bose R. The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast CancerNeratinib and Fulvestrant in HER2-Mutated Breast Cancer. Clinical Cancer Research 2022, 28: 1258-1267. PMID: 35046057, DOI: 10.1158/1078-0432.ccr-21-3418.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerBreast cancerER cohortEstrogen receptor-positive breast cancerReceptor-positive breast cancerClinical benefit rateDual HER2 blockadePhase II trialEfficacy of neratinibHER2 blockadeNeratinib monotherapyStable diseaseII trialHER2 mutationsLobular histologyPartial responseEndocrine resistanceBenefit ratePatientsFurther evaluationCancerFulvestrantHER2NeratinibProgression
2015
Direct-Conversion Molecular Breast Imaging of Invasive Breast Cancer: Imaging Features, Extent of Invasive Disease, and Comparison Between Invasive Ductal and Lobular Histology.
Conners AL, Jones KN, Hruska CB, Geske JR, Boughey JC, Rhodes DJ. Direct-Conversion Molecular Breast Imaging of Invasive Breast Cancer: Imaging Features, Extent of Invasive Disease, and Comparison Between Invasive Ductal and Lobular Histology. American Journal Of Roentgenology 2015, 205: w374-81. PMID: 26295674, PMCID: PMC8900216, DOI: 10.2214/ajr.14.13502.Peer-Reviewed Original ResearchConceptsInvasive breast cancerMolecular breast imagingInvasive tumor fociBreast imaging examinationsTumor fociMolecular breastBreast cancerImaging featuresInvasive diseasePathology reportsImaging examinationsHistologic profileBreast imagingBreast imaging findingsChi-square testLobular histologyHistologic subtypeInvasive DuctalImaging findingsInvasive cancerBenign reasonsInvasive fociTumor appearanceBlinded reviewLesion type
2011
PD05-07: Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer.
Olson E, Flores L, Najita J, Curley C, Jeong J, Murray K, Savoie J, Winer E, Krop I. PD05-07: Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer. Cancer Research 2011, 71: pd05-07-pd05-07. DOI: 10.1158/0008-5472.sabcs11-pd05-07.Peer-Reviewed Original ResearchHER2-positive CTCsMetastatic breast cancerHER2-negative metastatic breast cancerNegative metastatic breast cancerHER2-negative CTCsER-positive diseasePositive CTCsBreast cancerDetectable CTCsLobular histologyPositive diseaseNegative CTCsHER2 amplificationProspective validationHER2-Positive Circulating Tumor CellsHER2-negative breast cancerCEP17 ratioTumor cellsInitial screeningMajority of ptsNegative breast cancerHER2/CEP17 ratioCirculating Tumor CellsDuctal histologyBaseline characteristicsCharacteristics of multifocal and multicentric breast cancers detetected by preoperative MRI.
Killelea B, Grube B, Philpotts L, Sowden M, Horowitz N, Lannin D. Characteristics of multifocal and multicentric breast cancers detetected by preoperative MRI. Journal Of Clinical Oncology 2011, 29: 67-67. DOI: 10.1200/jco.2011.29.27_suppl.67.Peer-Reviewed Original ResearchBreast cancer patientsSecond tumorPreoperative MRISecond malignanciesPR statusCancer patientsBreast cancerER/PR statusMulticentric breast cancerSuspicious MRI findingsNumber of patientsDiagnosis of cancerLobular histologyNodal statusContralateral breastMRI findingsNode positiveTumor characteristicsTumor sizeHER2 statusAdditional tumorsSecondary lesionsSecondary tumorsPatientsControl groupDifferential expression of prognostic biomarkers between interval and screen-detected breast cancers: does age or family history matter?
Lowery J, Byers T, Kittelson J, Hokanson J, Mouchawar J, Lewin J, Merrick D, Hines L, Singh M. Differential expression of prognostic biomarkers between interval and screen-detected breast cancers: does age or family history matter? Breast Cancer Research And Treatment 2011, 129: 211-219. PMID: 21431872, PMCID: PMC4675131, DOI: 10.1007/s10549-011-1448-8.Peer-Reviewed Original ResearchConceptsScreen-detected cancersScreen-detected breast cancerInterval cancersBreast cancerPrognostic biomarkerTriple negative statusInterval breast cancersScreen-detected tumorsFamilial riskFisher's exact testTissue micro arrayLobular histologyProgesterone receptorCancer Genetics NetworkExact testNegative statusOverexpress EGFRDifferential expressionCompare protein expressionImmuno-stainingProtein expressionCancerEGFROlder womenTherapeutic target
1993
Conservative surgery and radiation in the treatment of synchronous ipsilateral breast cancers
Wilson L, Beinfield M, McKhann C, Haffty B. Conservative surgery and radiation in the treatment of synchronous ipsilateral breast cancers. Cancer 1993, 72: 137-142. PMID: 8389664, DOI: 10.1002/1097-0142(19930701)72:1<137::aid-cncr2820720126>3.0.co;2-e.Peer-Reviewed Original ResearchConceptsIpsilateral breast cancerConservative surgeryRadiation therapyRecurrence rateBreast cancerBreast recurrence rateChest wall progressionIpsilateral breast recurrenceActuarial survival rateEvidence of diseaseLocal recurrence rateManagement of patientsSubsequent local recurrenceInvasive lobular histologyBreast recurrenceLobular histologyMedian doseMetastatic diseaseLocal recurrenceThird patientRegional lymphaticsSeparate lesionsSingle lesionSame breastPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply